Arteris' ability to surpass both EPS and sales estimates for Q1 2024 indicates a positive performance against market expectations, which is likely to instill investor confidence and potentially lead to a short-term positive impact on its stock price. The improvement in EPS compared to the same period last year, despite a slight decrease in sales, suggests operational efficiency and cost management that could be viewed favorably by investors.